NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 6 Issue 3 Page 97-101, 2025

©NIJSES PUBLICATIONS ONLINE ISSN:2992-5819
Open Access PRINT ISSN:2992-6149

https://doi.org/10.59298/NIJSES/2025/63.97101

Efficacy of Gene-Drive Modified Mosquitoes in Reducing Malaria Transmission among Children in Sub-Saharan Africa: A Controlled Review

Arionget Jemima

Department of Pharmacoepidemeology Kampala International University Uganda
Email: jemima.arionget@studwc.kiu.ac.ug

ABSTRACT

Malaria remains a leading cause of morbidity and mortality among children in sub-Saharan Africa despite existing vector control and treatment strategies. Gene-drive modified mosquitoes have emerged as a novel approach to reduce malaria transmission sustainably by biasing inheritance to suppress mosquito populations or render them refractory to *Plasmodium* infection. This controlled review evaluated the efficacy of gene-drive modified mosquitoes in reducing malaria transmission among children in sub-Saharan Africa, synthesising evidence from laboratory, semi-field, and modelling studies. A controlled review approach was conducted by searching PubMed, Scopus, and Web of Science for articles published between 2010 and 2025 that assessed gene-drive mosquito efficacy in malaria control among children in endemic regions. Laboratory and semi-field studies demonstrate high inheritance rates of gene-drive constructs targeting mosquito fertility or parasite development, leading to rapid population suppression or refractoriness with minimal fitness costs. Modelling studies predict >90% reduction in malaria prevalence within 3–5 years of release, with significant declines in infection incidence, morbidity, and mortality among children. However, field-based efficacy data remain unavailable, and challenges such as resistance evolution, ecological impacts, regulatory preparedness, and ethical concerns regarding community consent and intergenerational effects persist. Gene-drive modified mosquitoes hold promise as a transformative vector control strategy to reduce malaria transmission among children in sub-Saharan Africa. Field trials, robust governance frameworks, and community-led ethical engagement are required to ensure safe, effective, and equitable deployment within integrated malaria elimination programmes.

Keywords: Gene drive, Malaria control, Mosquitoes, Sub-Saharan Africa, Children.

INTRODUCTION

Malaria remains a formidable public health challenge in sub-Saharan Africa, accounting for over 90% of global malaria cases and deaths [1, 2]. Children under five years of age bear a disproportionate burden, experiencing repeated infections that contribute to severe morbidity, mortality, and long-term developmental impairments [3, 4]. Despite widespread implementation of core interventions such as insecticide-treated nets (ITNs), indoor residual spraying (IRS), and artemisinin-based combination therapies (ACTs), malaria transmission persists in many high-burden regions due to factors including insecticide resistance, behavioural adaptation of mosquito vectors, and operational challenges in intervention coverage and sustainability.

Innovative approaches targeting vector populations are urgently needed to complement existing tools and accelerate progress towards malaria elimination. One such strategy is the deployment of gene-drive modified mosquitoes. Gene drives utilise genetic engineering techniques to bias inheritance patterns, ensuring that specific genes are preferentially transmitted to offspring [5]. In malaria control, gene-drive systems are designed to either reduce vector populations by impairing fertility or render mosquitoes refractory to *Plasmodium* infection, thereby interrupting transmission cycles [6]. Advances in CRISPR-Cas9 technology have facilitated the development of gene-drive constructs with high transmission efficiency and minimal fitness costs, offering unprecedented potential for sustainable, area-wide malaria control. However, the efficacy of gene-drive modified mosquitoes in reducing malaria transmission among children in sub-Saharan Africa remains a topic of intense scientific, ethical, and policy debate. While laboratory and semi-field studies demonstrate promising outcomes, field-based evidence in endemic settings is limited. This controlled review synthesises current data on gene-drive mosquito efficacy, evaluates their impact on malaria transmission among children, and explores operational, ecological, and ethical considerations for their potential integration into malaria elimination programmes in sub-Saharan Africa.

METHODOLOGY

A controlled review approach was utilised to synthesise evidence from peer-reviewed articles, preprints, and institutional reports published between 2010 and 2025. Databases searched included PubMed, Scopus, and Web of Science, focusing on studies assessing gene-drive mosquito efficacy in malaria transmission reduction among children in sub-Saharan Africa. Inclusion criteria encompassed laboratory, semi-field, and modelling studies with outcomes relevant to transmission reduction or child health impact.

Mechanisms of Gene-Drive Technology in Malaria Control

Gene drives function by biasing the inheritance of specific genetic traits within populations, overriding the conventional Mendelian 50% inheritance pattern [7]. Two primary gene-drive strategies are under development for malaria control. Both approaches aim to reduce malaria transmission intensity by reducing vector density or vector competence, respectively. The choice of strategy depends on local ecological, epidemiological, and sociopolitical contexts.

i. **Population Suppression Drives:** Population suppression drives target mosquito fertility genes (e.g., *doublesex* in *Anopheles gambiae*), leading to sterility in females and consequent population collapse [8]. CRISPR-Cas9-driven targeting of *doublesex* has shown rapid population elimination in laboratory cages within 7–11 generations.
ii. **Population Modification Drives:** Population modification drives insert genes rendering mosquito's refractory to *Plasmodium* infection [9]. Effector genes target parasite development stages, preventing maturation and transmission, while the gene drive ensures rapid spread of refractoriness within mosquito populations.

Evidence from Laboratory and Semi-Field Studies

i. **Laboratory Cage Trials:** Initial laboratory studies demonstrated near-complete spread of gene-drive constructs within controlled mosquito populations. Hammond et al. (2016) showed >95% transmission efficiency of CRISPR-based *doublesex* gene drives, leading to population collapse within months [10]. Similar results were observed for population modification drives inserting anti-*Plasmodium* effector genes.
ii. **Semi-Field Trials:** Semi-field studies conducted in contained environments mimicking African ecological conditions have demonstrated that gene-drive mosquitoes effectively spread desired traits under near-natural settings. For example, experiments in Burkina Faso's semi-field facilities showed high inheritance rates and no significant fitness costs, indicating potential for field deployment [11]. However, these studies did not directly measure malaria transmission outcomes in human populations.

Modelling Studies on Malaria Transmission Reduction

Given limited field data, mathematical models have been used to predict the impact of gene-drive mosquitoes on malaria transmission among children in sub-Saharan Africa [12]. Models suggest that combining gene-drive releases with existing interventions such as ITNs and IRS yields synergistic effects, accelerating malaria elimination timelines and reducing child mortality significantly. Key findings include:

i. Population suppression drives targeting *An. gambiae* could reduce malaria prevalence by >90% within 3–5 years post-release, assuming efficient drive propagation and minimal resistance evolution [12].
ii. Population modification drives rendering mosquitoes refractory to *Plasmodium falciparum* could achieve similar reductions if release coverage exceeds 50–70% of local vector populations [13].

Potential Impact on Child Health Outcomes

Although direct clinical trial data are unavailable, projected impacts based on entomological inoculation rate (EIR) reductions indicate substantial benefits for child health. However, these benefits depend on successful field deployment, community acceptance, and robust monitoring to track impact and detect resistance evolution. These benefits include:

i. **Reduced infection incidence:** Lower vector density and infectivity decrease the frequency of child infections, reducing anaemia, cognitive impairment, and mortality [14].

ii. **Enhanced herd protection:** Area-wide effects extend protection to non-users of conventional interventions, addressing coverage gaps in vulnerable populations.
iii. **Long-term sustainability:** Unlike insecticide-based interventions requiring recurrent deployment, gene drives offer self-sustaining benefits with potentially single-release implementation [15].

Operational and Ecological Considerations

i. Resistance Evolution: Emergence of drive-resistant alleles through non-homologous end joining or pre-existing genetic variation poses a threat to long-term efficacy [16]. Strategies under investigation include multiplexed guide RNAs targeting multiple sites to reduce resistance emergence.

ii. Ecological Impacts: Potential non-target effects on ecosystems, such as disruption of food webs reliant on mosquito populations, remain poorly understood. Ecological modelling and phased testing are essential to assess these risks before large-scale release.
iii. Regulatory Frameworks: Field deployment requires approval from national regulatory agencies and adherence to WHO guidance on genetically modified organisms (GMOs) [17]. Existing regulatory structures in many sub-Saharan African countries are underdeveloped for gene-drive technologies, necessitating capacity building and international collaboration.

Ethical, Legal, and Social Considerations

Robust ethical guidelines, community engagement frameworks, and participatory decision-making processes are critical to ensure just and acceptable deployment. Gene-drive interventions raise unique ethical questions:

i. **Informed community consent:** Given the area-wide spread of Gene-Drive Modified Mosquitoes, community-wide engagement and consent are essential, transcending individual autonomy models [18].
ii. **Intergenerational implications:** Potential irreversible ecological changes require intergenerational ethical assessment frameworks.
iii. **Governance and equity:** Decisions about the deployment of Gene-Drive Modified Mosquitoes must ensure equitable benefits for endemic communities and avoid exploitation by external research interests [19].

Field Trials: Current Status and Future Directions

The Target Malaria consortium, the leading gene-drive research initiative in Africa, has completed initial releases of non-gene-drive sterile male mosquitoes in Burkina Faso to build regulatory and community engagement foundations [20]. Gene-drive mosquito releases are projected within the next 5–10 years, following phased safety, efficacy, and environmental impact evaluations.

Future research priorities include:

i. **Field efficacy trials:** Direct measurement of malaria incidence reduction in child populations post-release.
ii. **Resistance management:** Development of second-generation drives with resistance mitigation mechanisms.
iii. **Combined intervention modelling:** Optimising deployment strategies integrating gene drives with existing vector control tools.
iv. **Community-led governance frameworks:** Empowering local stakeholders to guide decision-making and benefit-sharing mechanisms.

CONCLUSION

Gene-drive modified mosquitoes represent a promising frontier in malaria vector control with the potential to significantly reduce malaria transmission and child morbidity and mortality in sub-Saharan Africa. Laboratory and modelling studies indicate that both population suppression and modification drives can achieve substantial reductions in malaria prevalence when deployed effectively. However, the absence of field-based efficacy data underscores the need for cautious, phased implementation grounded in robust safety, ecological, and ethical assessments. Operational challenges, including resistance evolution, regulatory preparedness, and community acceptance, must be addressed through interdisciplinary research and participatory governance. As gene-drive technologies approach potential field deployment, prioritising child-centred health impact evaluations, transparent stakeholder engagement, and capacity building in endemic countries will be critical to ensuring their safe, effective, and equitable integration into malaria elimination programmes. Ultimately, gene-drive mosquitoes may complement existing interventions to transform malaria control trajectories, but their real-world efficacy and societal acceptance will determine their role in protecting the health and futures of Africa's children.

REFERENCES

1. Tufail, T., Agu, P. C., Akinloye, D. I., & Obaroh, I. O. (2024). Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. *Medicine*, *103*(49), e40241. doi: 10.1097/MD.0000000000040241. PMID: 39654176

2. Ogbonnia Egwu, C., Aloke, C., Chukwu, J., Agwu, A., Alum, E., Tsamesidis, I., M Aja, P., E Offor, C., Ajuka Obasi, N.: A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. Afr Health Sci. 22, 627–640 (2022). https://doi.org/10.4314/ahs.v22i4.68
3. Kungu, E., Inyangat, R., Ugwu, O.P.C. and Alum, E. U. (2023). Exploration of Medicinal Plants Used in the Management of Malaria in Uganda. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES 4(1):101-108. https://nijournals.org/wp-content/uploads/2023/10/NIJRMS-41101-108-2023.docx.pdf.
4. Ainebyoona, C., Egwu, C.O., Onohuean, H., Echegu, D.A. Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication (2025). Ethiopian Journal of Health Sciences, 2025; 35(3): 205-217.
5. Champer, J., Buchman, A., Akbari, O.S.: Cheating evolution: engineering gene drives to manipulate the fate of wild populations. Nature Reviews Genetics 2016 17:3. 17, 146–159 (2016). https://doi.org/10.1038/nrg.2015.34
6. Tajudeen, Y.A., Oladipo, H.J., Oladunjoye, I.O., Oladipo, M.K., Shittu, H.D., Abdulmumeen, I.F., Afolabi, A.O., El-Sherbini, M.S.: Transforming malaria prevention and control: the prospects and challenges of gene drive technology for mosquito management. Ann Med. 55, 2302504 (2023). https://doi.org/10.1080/07853890.2024.2302504;SUBPAGE:STRING:FULL
7. Cutter, A.D.: Synthetic gene drives as an anthropogenic evolutionary force. Trends in Genetics. 39, 347–357 (2023). https://doi.org/10.1016/J.TIG.2023.02.010/ASSET/21AFC374-EE8D-409C-BD3E-2F11F5AC2B32/MAIN.ASSETS/GR2.SML
8. Kyrou, K., Hammond, A.M., Galizi, R., Kranjc, N., Burt, A., Beaghton, A.K., Nolan, T., Crisanti, A.: A CRISPR–Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes. Nat Biotechnol. 36, 1062–1071 (2018). https://doi.org/10.1038/NBT.4245;TECHMETA=41,42,44,70;SUBJMETA=1511,1513,1647,631;KWRD=GENETIC+ENGINEERING,GENETIC+TECHNIQUES
9. Adolfi, A., Gantz, V.M., Jasinskiene, N., Lee, H.F., Hwang, K., Terradas, G., Bulger, E.A., Ramaiah, A., Bennett, J.B., Emerson, J.J., Marshall, J.M., Bier, E., James, A.A.: Efficient population modification gene-drive rescue system in the malaria mosquito Anopheles stephensi. Nature Communications 2020 11:1. 11, 1–13 (2020). https://doi.org/10.1038/s41467-020-19426-0
10. Hammond, A., Pollegioni, P., Persampieri, T., North, A., Minuz, R., Trusso, A., Bucci, A., Kyrou, K., Morianou, I., Simoni, A., Nolan, T., Müller, R., Crisanti, A.: Gene-drive suppression of mosquito populations in large cages as a bridge between lab and field. Nature Communications 2021 12:1. 12, 1–9 (2021). https://doi.org/10.1038/s41467-021-24790-6
11. Mondal, A., Sanchez Castellanos, H.M., Marshall, J.M.: A model-informed target product profile for population modification gene drives for malaria control. medRxiv. 2024.08.16.24312136 (2024). https://doi.org/10.1101/2024.08.16.24312136
12. James, S., Collins, F.H., Welkhoff, P.A., Emerson, C., J Godfray, H.C., Gottlieb, M., Greenwood, B., Lindsay, S.W., Mbogo, C.M., Okumu, F.O., Quemada, H., Savadogo, M., Singh, J.A., Tountas, K.H., Toure, Y.T.: Pathway to Deployment of Gene Drive Mosquitoes as a Potential Biocontrol Tool for Elimination of Malaria in Sub-Saharan Africa: Recommendations of a Scientific Working Group. Am J Trop Med Hyg. 98, 1 (2018). https://doi.org/10.4269/AJTMH.18-0083
13. Ferguson, N.M.: Challenges and opportunities in controlling mosquito-borne infections. Nature 2018 559:7715. 559, 490–497 (2018). https://doi.org/10.1038/s41586-018-0318-5
14. Cheaveau, J., Mogollon, D.C., Mohon, M.A.N., Golassa, L., Yewhalaw, D., Pillai, D.R.: Asymptomatic malaria in the clinical and public health context. Expert Rev Anti Infect Ther. 17, 997–1010 (2019). https://doi.org/10.1080/14787210.2019.1693259;WGROUP:STRING:PUBLICATION
15. D'Amato, R., Taxiarchi, C., Galardini, M., Trusso, A., Minuz, R.L., Grilli, S., Somerville, A.G.T., Shittu, D., Khalil, A.S., Galizi, R., Crisanti, A., Simoni, A., Müller, R.: Anti-CRISPR Anopheles mosquitoes inhibit gene drive spread under challenging behavioural conditions in large cages. Nature Communications 2024 15:1. 15, 1–12 (2024). https://doi.org/10.1038/s41467-024-44907-x
16. Zhao, Y., Li, L., Wei, L., Wang, Y., Han, Z.: Advancements and Future Prospects of CRISPR-Cas-Based Population Replacement Strategies in Insect Pest Management. Insects 2024, Vol. 15, Page 653. 15, 653 (2024). https://doi.org/10.3390/INSECTS15090653
17. Moretti, R., Lim, J.T., Ferreira, A.G.A., Ponti, L., Giovanetti, M., Yi, C.J., Tewari, P., Cholvi, M., Crawford, J., Gutierrez, A.P., Dobson, S.L., Ross, P.A.: Exploiting Wolbachia as a Tool for Mosquito-Borne Disease

Control: Pursuing Efficacy, Safety, and Sustainability. Pathogens. 14, 285 (2025). https://doi.org/10.3390/PATHOGENS14030285
18. Critical Geographies of Biotechnology Governance: A Case Study of Genetically Modified Mosquitoes for Vector-Borne Disease Control, https://ucalgary.scholaris.ca/items/7348121e-ccb2-4988-84a9-0f98bc3a3913
19. James, S.L., Dass, B., Quemada, H.: Regulatory and policy considerations for the implementation of gene drive-modified mosquitoes to prevent malaria transmission. Transgenic Res. 32, 17–32 (2023). https://doi.org/10.1007/S11248-023-00335-Z/TABLES/1
20. Pare Toe, L., Barry, N., Ky, A.D., Kekele, S., Meda, W., Bayala, K., Drabo, M., Thizy, D., Diabate, A.: Small-scale release of non-gene drive mosquitoes in Burkina Faso: from engagement implementation to assessment, a learning journey. Malaria Journal 2021 20:1. 20, 1–18 (2021). https://doi.org/10.1186/S12936-021-03929-2

CITE AS: Arionget Jemima (2025). Efficacy of Gene-Drive Modified Mosquitoes in Reducing Malaria Transmission among Children in Sub-Saharan Africa: A Controlled Review. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 6(3):97-101 https://doi.org/10.59298/NIJSES/2025/63.97101